SCA
TCRT icon

SAC Capital Advisors’s Alaunos Therapeutics TCRT Stock Holding History

SAC Capital Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-155
Closed -$106K – 907
2014
Q1 		$106K Buy
+155
New +$104K ﹤0.01% 1668
2013
Q3 		– Sell
-5,920
Closed -$1.86M – 1940
2013
Q2 		$1.86M Buy
+5,920
New +$1.64M 0.01% 773

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SAC Capital Advisors's TCRT Position: Q2 2014 in Review

SAC Capital Advisors sold out of Alaunos Therapeutics (TCRT) in Q2 2014, closing a stake of 155 shares — an estimated $106K sold.

SAC Capital Advisors first reported a position in TCRT in Q2 2013 and held it in 2 quarters. The position peaked at $1.86M in Q2 2013. 92 funds tracked by Wall St. Rank hold TCRT as of Q2 2014.

  • SAC Capital Advisors reported no remaining Alaunos Therapeutics position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 155 Alaunos Therapeutics shares in Q2 2014, an estimated $106K.
  • SAC Capital Advisors first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 2 quarters.
  • SAC Capital Advisors's Alaunos Therapeutics position peaked at $1.86M in Q2 2013.
  • 92 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.